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Abstract Glutamate (Glu) plays a key role in excitotox-
icity-related injury in cerebral ischemia. In the brain, Glu
homeostasis depends on Glu transporters, including the
excitatory amino acid transporters and the cysteine/Glu
antiporter (xc-). We hypothesized that drugs acting on Glu
transporters, such as ceftriaxone (CEF, 200 mg/kg, i.p.)
and N-acetylcysteine (NAC, 150 mg/kg, i.p.), administered
repeatedly for 5 days before focal cerebral ischemia in rats
and induced by a 90-min middle cerebral artery occlusion
(MCAO), may induce brain tolerance to ischemia. We
compared the effects of these drugs on brain infarct vol-
ume, neurological deficits and the mRNA and protein
expression of the Glu transporter-1 (GLT-1) and xc- with
the effects of ischemic preconditioning and chemical pre-
conditioning using 3-nitropropionic acid. Administration of
CEF and NAC significantly reduced infarct size and neu-
rological deficits caused by a 90-min MCAO. These ben-
eficial effects were accompanied by changes in GLT-1
expression caused by a 90-min MCAO at both the mRNA
and protein levels in the frontal cortex, hippocampus, and
dorsal striatum. Thus, the results of this study suggest that
the regulation of GLT-1 and xc- plays a role in the
development of cerebral tolerance to ischemia and that this
regulation may be a novel approach in the therapy of brain
ischemia.
Keywords Brain ischemia  Brain preconditioning 
N-acetylcysteine  Ceftriaxone  Neuroprotection
Introduction
Excitotoxicity related to excessive glutamate (Glu) release
plays an important role in the pathophysiology of brain
ischemia (Globus et al. 1991). The glial high-affinity glu-
tamate transporter 1 (GLT-1) and the cysteine/Glu anti-
porter xc- cooperate to actively regulate the concentration
of extracellular Glu (Danbolt 2001; Sato et al. 1999). Brain
ischemia is accompanied by a massive release of Glu; thus,
the role of both GLT-1 and xc- in this phenomenon is
important. Moreover, modulation of the glutaminergic
system is also associated with ischemic preconditioning
(IP). In this process, the brain develops a tolerance to
severe, damaging ischemia by previous exposure to low-
intensity and potentially damaging agents such as short-
term ischemia. Transient, but deleterious, global brain
ischemia decreased GLT-1 protein expression (Raghaven-
dra Rao et al. 2000), whereas IP upregulated GLT-1
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expression (Liu et al. 2011) and reduced an ischemia-in-
duced Glu release (Romera et al. 2007). Xc- has been
implicated in the release of Glu in exchange with cystine
from astrocytes and microglia and thereby in the induction
of neuronal cell death by excitotoxicity (Piani and Fontana
1994).
These findings suggest that the pharmacological modu-
lation of GLT-1 and xc- could have important therapeutic
implications. b-lactam antibiotics, including ceftriaxone
(CEF), upregulate GLT-1 expression and present neuro-
protective effects (Rothstein et al. 2005). Intraperitoneal
(i.p.) administration of CEF for 5 consecutive days prior to
90 min of a middle cerebral artery occlusion (MCAO)
reduced infarct volume and neurological deficits in rats
(Chu et al. 2007). Substances that affect xc- can also
attenuate the Glu excitotoxicity. For example, N-acetyl-
cysteine (NAC) is known to modulate the neuroprotective
effects of xc- (Lewerenz et al. 2013) in the brain ischemia
model (Sekhon et al. 2003).
We sought to investigate the neuroprotective effects of
CEF and NAC in the MCAO brain ischemia model and
their influence on the expression of GLT-1 and xc-. This is
the first report that reveals the influence of NAC and
3-nitropropionic acid (3NP) on these Glu transporters in the
90 min MCAO model. In addition, the comparison of
pharmacological interventions with the reference precon-
ditioning strategies (IP or 3NP) described in this study is
also an innovative approach.
Materials and Methods
Animals
All experiments were performed on male Wistar rats
(280–320 g; Charles River, USA). The animals were kept
on a normal day–night cycle at 22 ± 2 C with free access
to food and water. The study was carried out in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health and was
approved by the First Local Ethical Committee on Animal
Testing at the Jagiellonian University in Krakow (permit:
78/2011). All studies involving animals are reported
according to the ARRIVE (Animal Research: Reporting of
In Vivo Experiments) guidelines, including the blinding
procedure of animal identities on each level of experiments.
Drugs and Experimental Design
CEF (Biotrakson, Polpharma, Poland), NAC (Sigma Aldrich,
USA), and 3NP (Sigma Aldrich, USA) were dissolved in
saline (the NAC and 3NP solutions were neutralized with
10 % NaOH solution). Rats either received CEF (200 mg/kg),
NAC (150 mg/kg), or saline i.p. for 5 consecutive days. 3NP
was administered in a single dose of 20 mg/kg i.p. The
injection volume was 1 lL/g of body weight.
Three days after the last injection (saline, CEF, NAC, or
3NP), 90-min MCAO or sham surgery was performed. The
animals were randomly assigned to the following groups:
sham surgery (SHAM), 90-min MCAO (ISCH), 20-min
MCAO 3 days prior to sham operation (IP), 20-min MCAO
3 days prior to 90-min of occlusion (IP ? ISCH), NAC
administration 3 days prior to sham operation (NAC),
NAC administration prior to 90-min MCAO (NAC ?
ISCH), CEF administration 3 days prior to sham operation
(CEF), CEF administration 3 days prior to 90-min MCAO
(CEF ? ISCH), 3NP administration 3 days prior to sham
operation (3NP) and 3NP administration 3 days prior to
90-min MCAO (3NP ? ISCH). Eight animals from each
group were dedicated to the real-time PCR analysis, eight
rats for the ELISA assay and eight for the evaluation of the
brain ischemia infarct volume by TTC staining. All ani-
mals underwent a neurological assessment.
Focal Cerebral Ischemia Model
Transient focal cerebral ischemia was induced in anes-
thetized rats by an intraluminal filament occlusion of the
left middle cerebral artery (MCA) according to the Koi-
zumi method using a silicone-coated filament (Doccol
Corp., USA) (Koizumi et al. 1986). The identity of the
animal was blinded to the operator. All surgical procedures
were conducted under a stereoscopic surgical microscope
(PZO Warszawa, Poland), and the physiological body
temperature was maintained with a heating blanket (Har-
vard Apparatus, UK). The effectiveness of the occlusion
was determined using a blood flowmeter (Perimed, Swe-
den). Anesthesia was induced by a ketamine/xylazine
(Ketamina, Sedazin, Biowet-Puławy, Poland) mixture (3/1,
v/v, respectively) administered i.p. Anesthetics were given
in 300 lL injections, containing 75 mg/kg of ketamine and
5 mg/kg of xylazine by body weight.
The occlusion times were 20 and 90 min for IP and
ISCH, respectively. After the occlusion, the filament was
withdrawn to restore blood flow. Sham operations were
carried out as a MCAO except for the insertion of the
filament.
Neurological Evaluation
Functional assessments of animals were conducted with the
identities blinded to the observer and performed 24 h after
surgery using the Philips grading system (Phillips et al.
2000). Neurobehavioral findings were scored on a 10 point
scale where 0 indicated no neurological deficit and 10
points indicated a maximal neurological deficit.
540 Neurotox Res (2016) 29:539–550
123
Evaluation of the Infarct Volume by TTC Staining
Rats were killed 24 h after reperfusion by decapitation.
Brains were immediately removed and sliced using a brain
matrix (Harvard Apparatus, USA). Coronal sec-
tions (2 mm thick) were stained with a 1 % solution of
2,3,5-triphenyltetrazolium chloride (TTC) dye (Sigma
Aldrich, USA) in 0.01 M phosphate-buffered saline (Sigma
Aldrich, USA) at 37 C for 10 min in the dark. Sec-
tions were fixed in 10 % phosphate-buffered formalin
(Sigma Aldrich, USA) overnight at 4 C. Brain slices were
photographed under the surgical microscope (PZO Wars-
zawa, Poland) equipped with a digital camera (Optica,
Italy) by an investigator blinded to subject identity. The
infarct area was determined by NIH ImageJ software
(National Institutes of Health, version 8.0) by the same
investigator. The infarct volume was calculated as a sum of
each outlined white area multiplied by the thickness of a
brain section and expressed in mm3.
Real-Time PCR
Rats were decapitated 24 h after reperfusion; the brains were
immediately removed and selected brain structures, the
frontal cortex, hippocampus, and dorsal striatum, were iso-
lated and immersed in RNAlater stabilization solution (Am-
bion, USA) for 24 h at 4 C to preserve the RNA. The total
RNA from the collected brain regions was extracted using
TRI Reagent (Zymo Research, USA) and purified with the
Direct-zol RNA MiniPrep Kit (Zymo Research, USA)
according to the manufacturer’s protocol, including the in-
column DNAse I treatment step. The isolated RNA was
stored until used at -80 C until used. Reverse transcription
reactions and real-time PCR were conducted using the Pri-
meQ real-time PCR system (Techne, USA). The total RNA
was subsequently transcribed into cDNA using the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche, USA)
according to the manufacturer’s procedure. The cDNA was
stored at -80 C until used. The relative cDNA quantifica-
tion of GLT-1, xCT (the light chain of xc-) and a reference
gene (glyceraldehyde 3-phosphate dehydrogenase, GAPDH)
was measured using the commercial TaqMan Gene Expres-
sion Assay (Applied Biosystems, USA). Real-time PCR was
performed using the Fast Start Universal Probe Master
(ROX) (Roche, USA) according to the manufacturer’s pro-
cedure. The expression levels of each gene were normalized
to GAPDH levels; the fold change in expression was deter-
mined using the DDc(t) method of relative quantification.
Enzyme-Linked Immunosorbent Assays (ELISA)
The expression of GLT-1 and xCT proteins were deter-
mined using ELISA 96 well Assay Kits (Cloud-Clone
Corp., USA). Animals were decapitated 24 h after reper-
fusion. Selected brain structures, the frontal cortex, hip-
pocampus, and dorsal striatum, were isolated and
immediately frozen on dry ice and stored at -80 C.
Briefly, 10 % (w/v) homogenates of brain structures were
prepared in ice-cold PBS with a mechanical homogenizer
(ProScientific Inc., USA) and an ultrasonic processor
(Hielscher-Ultrasound, Germany). Homogenates were
centrifuged at 100009g for 10 min at 4 C. The obtained
supernatants were diluted 1:1 in PBS and added to 96-well
plates, which were processed according to the manufac-
turer’s protocol. The optical density was read at a wave-
length of 450 nm on a multiwell plate reader (TECAN,
Switzerland).
Statistical Analyses
All data are expressed as the mean ± SEM. The protein/
mRNA expression data were analyzed using the two-way
ANOVA for factors pretreatment (CEF/NAC/3NP/IP),
surgery (SHAM or MCAO), and pretreatment 9 surgery.
If statistical significance was found through analysis using
ANOVAs, Tukey’s post hoc test was then conducted to test
comparisons. Moreover, a priori pairwise comparisons
between the ischemic and sham groups were made with
Student’s t test. Infarction volume data were analyzed
using Student’s t test. A Mann–Whitney test was applied
for the analysis of neurological deficits. A p\ 0.05 was
considered as statistically significant.
Results
Neurological Deficit
After a 90-min MCAO, the neurological deficits were
scored and received an average of 6.13 ± 0.35 points. All
interventions significantly improved the neurological sta-
tus. The reduction in test score when compared with a
90-min MCAO was as follows: 1.38 ± 0.38 points for
CEF ? ISCH (p\ 0.001), 1.75 ± 0.62 points for
NAC ? ISCH (p\ 0.001), 2.38 ± 0.96 for 3NP ? ISCH
(p\ 0.001), and 0.63 ± 0.38 points for IP ? ISCH
(p\ 0.001) (Fig. 1a). Animals that were only subjected to
preconditioning interventions showed no neurological
deficits.
Infarct Volume
Pretreatment with CEF, NAC, 3NP, or IP prior to a 90-min
MCAO significantly reduced the infarct volume by 53.97,
61.65, 43.34, and 47.01 mm3, respectively. The mean infarct
volumes were 43.18 ± 2.78 mm3 for CEF ? ISCH
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(t[14] = 6.67, p = 0.001), 35.50 ± 0.95 mm3 for NAC ?
ISCH (t[14 = 8.05], p = 0.001), 53.81 ± 5.04 mm3 for
3NP ? ISCH (t[14] = 4.75, p = 0.001) and 50.1 ±
3.66 mm3 for IP ? ISCH (t[14] = 5.58, p = 0.001) vs.
97.15 ± 7.60 mm3 for ISCH (Fig. 1b, c). Preconditioning
interventions without a subsequent 90 min MCAO did not
produce brain infarction.
GLT-1 mRNA Expression
In the ISCH group, the GLT-1 mRNA levels were signif-
icantly decreased in the frontal cortex (t[14] = 10.30,
p = 0.001), hippocampus (t[14] = 4.52, p = 0.002), and
dorsal striatum (t[14] = 2.81, p = 0.014) (Fig. 2a).
A two-way ANOVA revealed that CEF alone enhanced
GLT-1 expression in the dorsal striatum (p\ 0.001). A
priori comparisons with Student’s t test also showed a
significant increase of GLT-1 mRNA in the frontal cortex
(t[14] = 2.94, p = 0.026). Moreover, a priori Student’s
t test showed that CEF pretreatment in ischemic rats sig-
nificantly elevated the GLT-1 mRNA levels in the frontal
cortex (t[14] = 5.13, p = 0.001) (Fig. 2a; Table 1).
A priori Student’s t test showed that NAC alone reduced
GLT-1 mRNA expression in the hippocampus (t[14] =
2.44, p = 0.029); in the ISCH animals, NAC significantly
reduced GLT-1 expression in the dorsal striatum
(t[14] = 2.27, p = 0.039) (Fig. 2a; Table 1).
3NP pretreatment significantly decreased GLT-1 mRNA
expression as shown by ANOVA in the hippocampus of
sham-operated animals (p = 0.009) but increased GLT-1
mRNA in the frontal cortex of the ischemic group
(p = 0.002). A priori Student’s t test revealed that 3NP
alone in the intact frontal cortex significantly decreased
GLT-1 mRNA expression (t[14] = 2.58, p = 0.022)
(Fig. 2a; Table 1).
A two-way ANOVA revealed that IP alone significantly
decreased the GLT-1 mRNA levels in the frontal cortex
(p\ 0.001) and hippocampus (p\ 0.001). Moreover, a
priori Student’s t test showed a significant increase in GLT-
1 mRNA expression in ischemic animals subjected to prior
IP in the frontal cortex (t[14] = 2.84, p = 0.013) (Fig. 2a;
Table 1).
xc- mRNA Expression
In the ISCH group, xc- mRNA levels were significantly
reduced in both the frontal cortex (t[14] = 11.62,
p\ 0.001) and hippocampus (t[14] = 7.59, p\ 0.001)
(Fig. 3a).
A two-way ANOVA showed that CEF alone signifi-
cantly upregulated xc- mRNA expression only in the dorsal
striatum (p\ 0.001). In ischemic animals, CEF increased
xc- mRNA expression in the frontal cortex (p = 0.044);
however, a priori Student’s t test showed that CEF reduce
xc- mRNA in the hippocampus (t[14] = 4.91, p = 0.001)
and dorsal striatum (t[14] = 3.61, p = 0.003) of ischemic
animals (Fig. 3a; Table 1).
Two-way ANOVA revealed that in ischemic rats, NAC
administration resulted in an increase of xc- mRNA levels
in the frontal cortex (p\ 0.001) (Fig. 3a; Table 1).
The ANOVA showed that 3NP alone decreased xc-
mRNA expression in the frontal cortex (p = 0.003) and
hippocampus (p = 0.028). Compared with rats subjected to
90-min MCAO, 3NP administration significantly enhanced
xc- mRNA expression both in the frontal cortex and in the
hippocampus (p = 0.002 and p = 0.003, respectively)
(Fig. 3a; Table 1).
A two-way ANOVA revealed that IP alone downregu-
lated xc- mRNA expression in the frontal cortex and hip-
pocampus (p\ 0.001 and p\ 0.001, respectively),
Fig. 1 Neuroprotective effects of interventions. a Decreased neuro-
logical deficit 24 h after ischemia (***p\ 0.001 vs. ISCH, Mann–
Whitney, n = 24/group). b Representative TTC-stained brain sec-
tions and corresponding histogram c representing the calculated
infarct volume in ISCH, CEF ? ISCH, NAC ? ISCH, 3NP ? ISCH,
and IP ? ISCH groups (***p\ 0.001 vs. ISCH, t test, n = 8/group)
24 h after reperfusion. 3NP 3-nitropropionic acid, CEF ceftriaxone,
IP ischemic preconditioning, ISCH 90 min of occlusion, NAC N-
acetylcysteine, SHAM sham operated animals
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whereas in ischemic animals, ANOVA showed that IP
resulted in a significant increase of xc- mRNA in the
frontal cortex and hippocampus (p\ 0.001 and p\ 0.001,
respectively) (Fig. 3a; Table 1).
GLT-1 Protein Expression
In the ISCH group, a significant decrease of GLT-1 protein
levels was observed in the frontal cortex (t[14] = 7.38,
p\ 0.001), hippocampus (t[14] = 3.52, p = 0.003) and
dorsal striatum (t[14] = 7.99, p\ 0.001) (Fig. 2b).
In ischemic rats, a two-way ANOVA showed that CEF
pretreatment upregulated GLT-1 protein expression in the
frontal cortex and dorsal striatum (p = 0.003 and
p = 0.002, respectively). Moreover, a priori Student’s t test
showed an increase in GLT-1 protein expression in
ischemic hippocampus (t[14] = 2.82, p = 0.014) (Fig. 2b;
Table 1).
NAC alone, as revealed by ANOVA, reduced GLT-1
levels in the frontal cortex and hippocampus (p\ 0.001
and p = 0.01, respectively) (Fig. 2b; Table 1).
A two-way ANOVA showed that in ischemic animals 3NP
significantly raised GLT-1 protein expression in the hip-
pocampus to SHAM levels (p = 0.026). Moreover, a priori
Student’s t test indicated that in ischemic animals pretreat-
ment with 3NP significantly increased GLT-1 expression in
the frontal cortex (t[14] = 3.56, p = 0.003) and dorsal
striatum (t[14] = 3.16, p = 0.007) (Fig. 2b; Table 1).
Fig. 2 Influence of
interventions on the expression
of mRNA (a) and protein (b) of
GLT-1 in the frontal cortex
(FC), hippocampus (HIP) and
dorsal striatum (DS) in the
following groups: SHAM,
ISCH, CEF, CEF ? ISCH,
NAC, NAC ? ISCH, 3NP,
3NP ? ISCH, IP ? ISCH, and
IP (*p\ 0.05, **p\ 0.01,
***p\ 0.001 vs. ISCH or
SHAM, Student’s t test,
#p\ 0.05, ##p\ 0.01,
###p\ 0.001 vs. ISCH or
SHAM, Two-way ANOVA,
Post hoc Tukey’s test,
n = 8/group) 24 h after
reperfusion. 3NP
3-nitropropionic acid, CEF
ceftriaxone, IP ischemic
preconditioning, ISCH 90 min
of occlusion, NAC N-
acetylcysteine; SHAM sham
operated animals
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Similar results were observed in the IP groups. A two-
way ANOVA revealed that in animals subjected to
ischemia, IP significantly increased GLT-1 protein
expression in the frontal cortex to the SHAM levels
(p\ 0.001). Moreover, a priori Student’s t test showed
significant increases in the hippocampus (t[14] = 2.27,
p = 0.04) and dorsal striatum (t[14] = 2.55, p = 0.023)
(Fig. 2b; Table 1).
xc- Protein Expression
After a 90-min MCAO, no changes in xc- protein levels
were found in any of the examined structures (Fig. 3b).
As shown by two-way ANOVA, CEF alone enhanced
the xc- protein expression in the frontal cortex (p = 0.001).
Interestingly, a priori Student’s t test showed reduced
levels of xc- protein in the dorsal striatum (t[14] = 2.67,
p = 0.019) (Fig. 3b; Table 1).
For NAC only treated rats, ANOVA showed a decrease
in xc- only in the dorsal striatum (p\ 0.001). However, in
the frontal cortex, as shown by Student’s t test, NAC
administration reduced the xc- protein levels (t[14] = 3.99,
p = 0.001). In ischemic rats, ANOVA showed that a prior
NAC injection reduced the xc- protein expression in the
dorsal striatum (p = 0.011). A priori Student’s t test
revealed that NAC also reduced xc- expression in the
Fig. 3 Influence of
interventions on the expression
of mRNA (a) and protein (b) of
xc- in the frontal cortex (FC),
hippocampus (HIP) and dorsal
striatum (DS) in the following
groups: SHAM, ISCH, CEF,
CEF ? ISCH, NAC,
NAC ? ISCH, 3NP,
3NP ? ISCH, IP ? ISCH, and
IP (*p\ 0.05, **p\ 0.01,
***p\ 0.001 vs. ISCH or
SHAM, Student’s t test,
#p\ 0.05, ##p\ 0.01,
###p\ 0.001 vs. ISCH or
SHAM, Two-way ANOVA,
Post hoc Tukey’s test,
n = 8/group) 24 h after
reperfusion. 3NP
3-nitropropionic acid, CEF
ceftriaxone, IP ischemic
preconditioning, ISCH 90 min
of occlusion, NAC N-
acetylcysteine, SHAM sham
operated animals
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frontal cortex (t[14] = 3.21, p = 0.006) and hippocampus
(t[14] = 2.32, p = 0.036) (Fig. 3b; Table 1).
In ischemic animals, a priori Student’s t test showed that
3NP reduced the xc- protein expression in the dorsal
striatum (t[14] = 2.78, p = 0.015) (Fig. 3b; Table 1),
whereas 3NP alone did not influence protein levels in any
of the structures examined.
In ISCH animals after IP, an a priori Student’s t test
showed that higher protein levels were found in the frontal
cortex (t[14] = 8.21, p\ 0.001), hippocampus (t[14] =
3.01, p = 0.008) and dorsal striatum (t[14] = 2.37,
p = 0.033) (Fig. 3b; Table 1). No significant changes were
found after IP alone.
Discussion
Ischemic stroke is one of the major causes of death and
disability in adults. Despite significant progress in patient
care, therapeutic options for stroke victims are limited, and
only a small percentage of patients are treated with
thrombolysis or by an endovascular approach. Thus, new
therapeutic strategies are urgently needed. The induction of
cerebral tolerance to ischemia is an intriguing phe-
nomenon. It is possible to make the brain more resistant to
damaging stimuli using chemical, pharmacological, or
physical interventions. The molecular biology of this
phenomenon is poorly understood. Glu-related excitotoxi-
city plays an important role in ischemic brain injury; thus,
modulation of the Glu transporters is a reasonable candi-
date mechanism that may be involved in the induction of
brain tolerance.
In the present study, we found that all four of the pre-
conditioning strategies that were investigated, i.e., CEF,
NAC, 3NP, and IP, were effective in protecting the brain
against prolonged focal ischemia in a MCAO model in rats.
Moreover, all of these interventions influenced the
expression of the two Glu transporters that were investi-
gated, GLT-1 and xc-.
In agreement with previous reports (Sanchez-Mendoza
et al. 2010; Ketheeswaranathan et al. 2011), we observed
that prolonged MCAO resulted in the decreased expression
of GLT-1 at both the mRNA and protein levels in all 3 of
the regions that were analyzed in the ischemic cerebral
hemisphere, the dorsal striatum, the frontal cortex, and the
hippocampus. The simplest mechanistic explanation for
this may be that glial and neuronal cells that express GLT-1
undergo ischemia-induced cell death. Intriguingly, a
90-min MCAO caused a significant drop in xc- mRNA
levels only in the frontal cortex and hippocampus. The
mRNA expression in the dorsal striatum and the protein
levels in all three of the investigated regions did not differ
significantly when compared with non-ischemic rats. As
suggested by Nurmi et al. 2004, this effect may be asso-
ciated with an increase in nuclear factor-kappa B (NFjB)
activity within the peri-infarct region (frontal cortex and
hippocampus) followed by the suppression of the xCT gene
(Nair et al. 2008). Why the mRNA and protein levels in the
dorsal striatum, the region that is most severely affected by
focal ischemia, did not change significantly remains
unclear. This phenomenon may be related to the distribu-
tion of the cellular sources of the xc- system, which are
predominantly expressed in meningeal, ependymal, and
microglial cells (Massie et al. 2015). These first two types
of cells were absent within the investigated striatal tissue.
Activated microglia in ischemic tissue are typically present
24 h after stroke (Thiel and Heiss 2011). Thus, a lack of
major cellular sources of the xc- system within the ana-
lyzed structures could result in a lack of significant changes
in the transporter expression. Another potential mechanism
responsible for the observed changes in xc- expression is
related to the Janus protein tyrosine kinases (JAK)/signal
transducers and activators (STAT) pathway. STAT3/
STAT5 negatively regulates the expression of xc- (Massie
et al. 2015), and the activation of STAT3 was shown in the
ischemic cortex and striatum of rats subjected to transient
MCAO (Justicia et al. 2000). Relatively stable protein
levels in the cortex and hippocampus, despite ischemia,
could result from different kinetics of mRNA and protein
expression.
Not surprisingly, both pharmacological pretreatments,
i.e., CEF and NAC, exerted different effects on the Glu
transporters GLT-1 and xc-. Compared with untreated
animals, CEF alone induced the expression of GLT-1
mRNA in the frontal cortex and striatum, but no significant
changes in protein levels were found in any of the studied
structures. Rothstein et al. (2005) first described the effects
of CEF on GLT-1 expression; many studies have since
confirmed that CEF enhances the expression of this trans-
porter. However, depending on the experimental model,
treatment paradigms, and animals used, there are several
discrepancies between the published results. For instance,
Thöne-Reineke et al. (2008) reported a lack of changes in
GLT-1 mRNA and protein levels in the hippocampus,
frontal cortex, and striatum after CEF administration,
whereas Lai et al. (2011) found that in neonatal rats, CEF
treatment induced GLT-1 protein levels in the cortex but
not in the striatum and hippocampus. These results raise
questions about the posttranscriptional regulation of GLT-1
expression in different brain regions.
In rats subjected to 90-min ischemia, a 5-day pretreat-
ment with CEF resulted in an increased expression of GLT-
1 mRNA only in the frontal cortex. In addition, the protein
levels were higher in all 3 regions compared with non-
preconditioned animals. These results are in agreement
with findings published by Verma et al. (2010). In the
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frontal cortex and hippocampus, which are periinfarct
areas, (both regions were largely spared in treated rats)
there is an increased expression of NFjB (Schneider et al.
1999), which plays a crucial role in enhancing GLT-1
expression by CEF (Lee et al. 2008). Increased protein
levels in rats pretreated with CEF and subjected to a
90-min MCAO were comparable with levels detected in
the SHAM group. Since the frontal cortex and hippocam-
pus were spared from ischemic damage, cellular loss may
have been minimal or not occurring within these two
regions. Whereas in the severely damaged dorsal striatum,
GLT-1 upregulation in the pretreated animals may reflect
an attempt to induce tolerance, but the lack of protection
against ischemia, despite increased GLT-1 protein
expression, could be related to the severity of ischemic
damage because this area is an ischemic core region. The
drop in blood flow in the dorsal striatum is the most severe
of the brain regions, and this tissue dies first (Gar-
cia et al. 1995). However, further studies to clarify the
regulatory action of CEF on GLT-1 in focal cerebral
ischemia are still needed.
A different pattern of changes was observed in the
expression of xc- after CEF administration. Compared with
sham-operated rats, CEF treatment resulted in an upregu-
lation of mRNA expression in the dorsal striatum, but
protein levels increased only in the frontal cortex. In ani-
mals subjected to a 90 min MCAO after CEF, increased
levels of xc- mRNA were found in the frontal cortex
compared with the non-treated group. However, signifi-
cantly lower amounts of mRNA in the hippocampus and
striatum were detected in pretreated rats. Given that xc-
exports Glu from cells, and in ischemia, excitotoxicity-
dependent injury is associated with a dramatic rise of
extracellular Glu (Lipton 1999), this downregulation of xc-
expression could be protective. Moreover, in response to
cerebral ischemia, microglial and astroglial cells are acti-
vated, and it is known that activated microglia and astro-
cytes release Glu via xc- that can kill neurons (Piani and
Fontana 1994; Fogal et al. 2007).
NAC administration caused different effects than CEF
on the Glu transporters investigated. In non-ischemic rats,
we observed lower levels of GLT-1 mRNA in the hip-
pocampus, lower GLT-1 protein in the hippocampus and
cortex and a lack of significant changes in the dorsal
striatum. Similarly, Knackstedt et al. (2010) analyzed
GLT-1 protein expression after chronic NAC treatment and
did not observe any changes in the nucleus accumbens
(ventral striatum). Additionally, in R6/1 mice, NAC failed
to influence GLT-1 expression in the cortex and striatum
(Wright et al. 2015). In animals subjected to a 90 min
MCAO, pretreatment with NAC resulted in decreased
GLT-1 mRNA expression only in the striatum with no
significant changes in protein levels, which differs from the
findings on CEF-induced effects. There is a general
agreement that GLT-1 is important in the induction of brain
tolerance, but results of published studies are inconsistent.
Several reports describe an increase in GLT-1 expression
after preconditioning stimulus (Pradillo et al. 2006;
Romera et al. 2007; Zhang et al. 2007; Bigdeli et al. 2008),
but there are also data suggesting that GLT-1 downregu-
lation is crucial to induce brain tolerance (Douen et al.
2000; Kosugi et al. 2005). Moreover, results of several
studies have suggested that an excess of extracellular Glu
after ischemia reversed the mode of action of GLT-1 and
subsequently augmented tissue damage (Douen et al. 2000;
Kosugi et al. 2005; Verma et al. 2010). Thus, downregu-
lation of GLT-1 expression could be protective. Since
NAC, among its various mechanisms of action, also inhi-
bits NFjB activation (Schreck et al. 1992), which can
induce GLT-1 expression, the observed downregulation of
GLT-1 expression could be partially driven by NFjB
activity. However, differences between the examined
cerebral regions raise a question about the area-specific
distribution and regulation of transporter expression.
NAC injection, both in ischemic and non-ischemic rats,
caused a significant drop in xc- protein levels in investi-
gated regions. As discussed above, the downregulation of
this transporter could be protective via a subsequent
decrease in Glu export from the cells, thereby decreasing
the extracellular Glu concentration, which plays a delete-
rious role in cerebral ischemia.
Interestingly, two of the other preconditioning methods
investigated, i.e., IP and 3NP, exerted identical effects on
the expression levels of GLT-1 among rats that were not
subjected to prolonged ischemia. IP and 3NP caused a
significant downregulation of GLT-1 mRNA levels in the
frontal cortex and hippocampus; however, GLT-1 protein
levels remained unchanged. After a subsequent 90 min
MCAO, the observed response resembled that found after
CEF pretreatment, i.e., higher levels of mRNA in the
frontal cortex and higher protein levels in all three of the
examined structures. These results suggest that GLT-1
plays an important protective role in the development of
brain tolerance to ischemia. Similar effects of IP in focal
cerebral ischemia were reported by Bigdeli et al. (2009).
To the best of our knowledge, the influence of 3NP on
GLT-1 in the context of brain tolerance has not been
reported. However, it should be noted that GLT-1 expres-
sion levels after a 90 min MCAO preceded by precondi-
tioning were comparable with the SHAM group levels.
Therefore, the GLT-1 protein levels could be related to the
preservation of cellular sources in the rescued regions (i.e.,
the frontal cortex and hippocampus) and unsuccessful
preconditioning within the infarction core (dorsal striatum).
The identical effects of 3NP and IP on GLT-1 expression
was consistent with their similar influence on the
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expression of proinflammatory cytokines such as IL-1b and
TNF-a, which are also regulated by NFjB (Pera et al.
2004), a well-recognized modulator of GLT-1 expression
(Takahashi et al. 2015).
3NP and IP exerted similar effects on xc- mRNA levels
but not on protein levels. Compared with SHAM rats,
preconditioning alone caused a decrease in the amount of
mRNA in the frontal cortex and hippocampus, which
mirrored changes observed in GLT-1 expression. Addi-
tionally, protein levels did not change significantly. How-
ever, in animals subjected to a 90 min MCAO, a prior
application of 3NP or IP resulted in increased mRNA
levels in the cortex and hippocampus, whereas protein
levels were lower in the striatum in 3NP rats and higher in
all three regions after IP. Moreover, this protein increase in
the frontal cortex exceeded the levels measured in the
SHAM animals. These results suggest that xc- is one of the
players in the protection caused by IP. What the underlying
mechanism is remains unclear. To the best of our knowl-
edge, this is the first study that has investigated the asso-
ciation between preconditioning with 3NP/IP and xc-
expression in focal brain ischemia. Sims et al. (2012)
showed that short-term hypoxia used as a preconditioning
stimulus upregulated xc- mRNA and protein expression
and changed xc- activity in the brain in C57BL/6 mice. In
hypoxic and IP, low-degree oxidative stress plays an
important role in the activation of the nuclear factor ery-
throid 2-related factor 2 (Nrf-2) (Thompson et al. 2012),
which can induce xc- expression (Massie et al. 2015). Nrf-
2 is also implicated in CEF-related neuroprotection
involving xc- (Lewerenz et al. 2009). However, in the
current study, the effects of CEF and IP on xc- expression
differed. In addition, preconditioning with 3NP is associ-
ated with oxidative stress and reactive oxygen species
generation (Wiegand et al. 1999). In contrast to IP rats, we
failed to detect any changes xc-protein levels after a
90 min MCAO, although both 3NP and IP showed similar
effects on mRNA expression. Altogether, these observa-
tions strongly suggest that the induction of brain tolerance
to ischemia is a very complex process and that different
preconditioning stimuli can evoke different effects on
particular pathways and molecules.
In summary, in the current study, we found that all four
of the tested strategies, i.e., CEF, NAC, 3NP, and IP,
induced brain tolerance to prolonged focal ischemia.
Pharmacological preconditioning with CEF and NAC
showed similar neuroprotective effects, measured as infarct
volume and neurological deficit, as two established
strategies. All of these strategies influenced the expression
of the Glu transporters investigated, suggesting that they
play an important role in the induction of brain tolerance.
However, the effects differed among the preconditioning
stimuli. CEF, 3NP, and IP upregulated GLT-1 protein
levels after prolonged ischemia, whereas GLT-1 appears
not to be the key target of action of NAC. Instead, after
NAC preconditioning, we found a significant downregu-
lation of xc- protein in ischemic brains. Interestingly, IP
prior to a 90-min MCAO resulted in an increased expres-
sion of this transporter.
Conclusions
In summary, CEF, NAC, 3NP, and IP showed neuropro-
tective effects after focal brain ischemia, indicating similar
reductions in neurological deficits. These effects were
associated with changes in the expression levels of two
glutamatergic system transporters, GLT-1 and xc-.
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